Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulacimstat in Diabetic Kidney Disease
NCT03412006Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in diabetic kidney disease (DKD) comparing Fulacimstat with Placebo (2 arms). Primary endpoint: Change in urinary albumin to creatinine ratio at 6 months. Started Feb 2018; status: completed.
02
Drugs
fulacimstat
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03412006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412006.